CircSMAD3 represses VSMC phenotype switching and neointima formation via promoting hnRNPA1 ubiquitination degradation

Abstract

Circular RNAs (circRNAs) are novel regulatory RNAs with high evolutionary conservation and stability, which makes them effective therapeutic agents for various vascular diseases. The SMAD family is a downstream mediator of the canonical transforming growth factor beta (TGF-β) signalling pathway and has been considered as a critical regulator in vascular injury. However, the role of circRNAs derived from the SMAD family members in vascular physiology remains unclear. In this study, we initially identified potential functional circRNAs originating from the SMAD family using integrated transcriptome screening. circSMAD3, derived from the SMAD3 gene, was identified to be significantly downregulated in vascular injury and atherosclerosis. Transcriptome analysis was conducted to comprehensively illustrate the pathways modulated by circRNAs. Functionally, circSMAD3 repressed vascular smooth muscle cell (VSMC) proliferation and phenotype switching in vitro evidenced by morphological assays, and ameliorated arterial injury-induced neointima formation in vivo. Mechanistically, circSMAD3 interacted with heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1) within the nucleus, enhanced its interaction with E3 ligase WD repeat domain 76 to promote hnRNPA1 ubiquitination degradation, facilitated p53 pre-RNA splicing, activated the p53γ signalling pathway, and finally suppressed VSMC proliferation and phenotype switching. Our study identifies circSMAD3 as a novel epigenetic regulator that suppresses VSMC proliferation and phenotype switching, thereby attenuating vascular remodelling and providing a new circRNA-based therapeutic strategy for cardiovascular diseases.

References

[1] MianoJM, FisherEA, MajeskyMW. Fate and state of vascular smooth muscle cells in atherosclerosis. Circulation. 2021;143(21):2110-2116.

[2] MorrowD, GuhaS, SweeneyC, et al. Notch and vascular smooth muscle cell phenotype. Circ Res. 2008;103(12):1370-1382.

[3] Davis-DusenberyBN, Wu C, HataA. Micromanaging vascular smooth muscle cell differentiation and phenotypic modulation. Arterioscler Thromb Vasc Biol. 2011;31(11):2370-2377.

[4] BasatemurGL, Jorgensen HF, ClarkeMCH, BennettMR, MallatZ. Vascular smooth muscle cells in atherosclerosis. Nat Rev Cardiol. 2019;16(12):727-744.

[5] OwensGK, KumarMS, WamhoffBR. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev. 2004;84(3):767-801.

[6] KristensenLS, Andersen MS, StagstedLVW, EbbesenKK, HansenTB, KjemsJ. The biogenesis, biology and characterization of circular RNAs. Nat Rev Genet. 2019;20(11):675-691.

[7] LiuCX, ChenLL. Circular RNAs: characterization, cellular roles, and applications. Cell. 2022;185(12):2016-2034.

[8] KohansalM, Alghanimi YK, BanoonSR, et al. CircRNA-associated ceRNA regulatory networks as emerging mechanisms governing the development and biophysiopathology of epilepsy. CNS Neurosci Ther. 2024;30(4):e14735.

[9] HuangX, SongC, ZhangJ, Zhu L, TangH. Circular RNAs in breast cancer diagnosis, treatment and prognosis. Oncol Res. 2023;32(2):241-249.

[10] WangZ, YangL, WuP, et al. The circROBO1/KLF5/FUS feedback loop regulates the liver metastasis of breast cancer by inhibiting the selective autophagy of afadin. Mol Cancer. 2022;21(1):29.

[11] HansenTB, JensenTI, ClausenBH, et al. Natural RNA circles function as efficient microRNA sponges. Nature. 2013;495(7441):384-388.

[12] LiQ, WangY, WuS, et al. CircACC1 regulates assembly and activation of AMPK complex under metabolic stress. Cell Metab. 2019;30(1):157-173.e7.

[13] HuangS, LiX, ZhengH, et al. Loss of super-enhancer-regulated circRNA Nfix induces cardiac regeneration after myocardial infarction in adult mice. Circulation. 2019;139(25):2857-2876.

[14] LiZ, HuangC, BaoC, et al. Exon-intron circular RNAs regulate transcription in the nucleus. Nat Struct Mol Biol. 2015;22(3):256-264.

[15] LegniniI, Di Timoteo G, RossiF, et al. Circ-ZNF609 is a circular RNA that can Be translated and functions in myogenesis. Mol Cell. 2017;66(1):22-37 e29.

[16] YangY, FanX, MaoM, et al. Extensive translation of circular RNAs driven by N(6)-methyladenosine. Cell Res. 2017;27(5):626-641.

[17] HallIF, Climent M, QuintavalleM, et al. Circ_Lrp6, a circular RNA enriched in vascular smooth muscle cells, acts as a sponge regulating miRNA-145 function. Circ Res. 2019;124(4):498-510.

[18] GongX, TianM, CaoN, et al. Circular RNA circEsyt2 regulates vascular smooth muscle cell remodeling via splicing regulation. J Clin Invest. 2021;131(24):e147031.

[19] LiuX, ZhangY, ZhouS, Dain L, MeiL, ZhuG. Circular RNA: an emerging frontier in RNA therapeutic targets, RNA therapeutics, and mRNA vaccines. J Control Release. 2022;348:84-94.

[20] MattickJS, AmaralPP, CarninciP, et al. Long non-coding RNAs: definitions, functions, challenges and recommendations. Nat Rev Mol Cell Biol. 2023;24(6):430-447.

[21] LiH, PengK, YangK, et al. Circular RNA cancer vaccines drive immunity in hard-to-treat malignancies. Theranostics. 2022;12(14):6422-6436.

[22] HuangD, ZhuX, YeS, et al. Tumour circular RNAs elicit anti-tumour immunity by encoding cryptic peptides. Nature. 2024;625(7995):593-602.

[23] QuL, YiZ, ShenY, et al. Circular RNA vaccines against SARS-CoV-2 and emerging variants. Cell. 2022;185(10):1728-1744.e16.

[24] SeephetdeeC, Bhukhai K, BuasriN, et al. A circular mRNA vaccine prototype producing VFLIP-X spike confers a broad neutralization of SARS-CoV-2 variants by mouse sera. Antiviral Res. 2022;204:105370.

[25] WangL, XuGE, SpanosM, et al. Circular RNAs in cardiovascular diseases: regulation and therapeutic applications. Research. 2023;6:38.

[26] NemethK, Bayraktar R, FerracinM, CalinGA. Non-coding RNAs in disease: from mechanisms to therapeutics. Nat Rev Genet. 2024;25(3):211-232.

[27] KangJS, LiuC, DerynckR. New regulatory mechanisms of TGF-beta receptor function. Trends Cell Biol. 2009;19(8):385-394.

[28] LiZ, KongW. Cellular signaling in abdominal aortic aneurysm. Cell Signal. 2020;70:109575.

[29] IsselbacherEM, Lino Cardenas CL, LindsayME. Hereditary influence in thoracic aortic aneurysm and dissection. Circulation. 2016;133(24):2516-2528.

[30] ten DijkeP, ArthurHM. Extracellular control of TGFbeta signalling in vascular development and disease. Nat Rev Mol Cell Biol. 2007;8(11):857-869.

[31] van den HovenAT, BonsLR, BaartSJ, et al. Aortic dimensions and clinical outcome in patients with SMAD3 mutations. Circ Genom Precis Med. 2018;11(11):e002329.

[32] RegaladoES, GuoDC, VillamizarC, et al. Exome sequencing identifies SMAD3 mutations as a cause of familial thoracic aortic aneurysm and dissection with intracranial and other arterial aneurysms. Circ Res. 2011;109(6):680-686.

[33] LiY, MaX, MeiS, et al. mRNA, lncRNA, and circRNA expression profiles in a new aortic dissection murine model induced by hypoxia and Ang II. Front Cardiovasc Med. 2022;9:984087.

[34] XiaoMS, AiY, WiluszJE. Biogenesis and functions of circular RNAs come into focus. Trends Cell Biol. 2020;30(3):226-240.

[35] JiaY, MaoC, MaZ, et al. PHB2 maintains the contractile phenotype of VSMCs by counteracting PKM2 splicing. Circ Res. 2022;131(10):807-824.

[36] ArmaosA, Colantoni A, ProiettiG, RupertJ, Tartaglia GG. catRAPID omics v2.0: going deeper and wider in the prediction of protein-RNA interactions. Nucleic Acids Res. 2021;49(W1):W72-W79.

[37] YanY, ZhangD, ZhouP, Li B, HuangSY. HDOCK: a web server for protein-protein and protein-DNA/RNA docking based on a hybrid strategy. Nucleic Acids Res. 2017;45(W1):W365-W373.

[38] LiM, ZhuangY, BatraR, et al. HNRNPA1-induced spliceopathy in a transgenic mouse model of myotonic dystrophy. Proc Natl Acad Sci USA. 2020;117(10):5472-5477.

[39] DavidCJ, ChenM, AssanahM, Canoll P, ManleyJL. HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature. 2010;463(7279):364-368.

[40] MarcelV, Dichtel-Danjoy ML, SagneC, et al. Biological functions of p53 isoforms through evolution: lessons from animal and cellular models. Cell Death Differ. 2011;18(12):1815-1824.

[41] WylieA, JonesAE, DasS, LuWJ, AbramsJM. Distinct p53 isoforms code for opposing transcriptional outcomes. Dev Cell. 2022;57(15):1833-1846.e6.

[42] ZhangX, GroenK, MortenBC, et al. Effect of p53 and its N-terminally truncated isoform, Delta40p53, on breast cancer migration and invasion. Mol Oncol. 2022;16(2):447-465.

[43] LevandowskiCB, JonesT, GrucaM, Ramamoorthy S, DowellRD, TaatjesDJ. The Delta40p53 isoform inhibits p53-dependent eRNA transcription and enables regulation by signal-specific transcription factors during p53 activation. PLoS Biol. 2021;19(8):e3001364.

[44] ChenJ, NgSM, ChangC, et al. p53 isoform delta113p53 is a p53 target gene that antagonizes p53 apoptotic activity via BclxL activation in zebrafish. Genes Dev. 2009;23(3):278-290.

[45] MondalAM, ZhouH, HorikawaI, et al. Delta133p53alpha, a natural p53 isoform, contributes to conditional reprogramming and long-term proliferation of primary epithelial cells. Cell Death Dis. 2018;9(7):750.

[46] ZhangT, CaoRJ, NiuJL, et al. G6PD maintains the VSMC synthetic phenotype and accelerates vascular neointimal hyperplasia by inhibiting the VDAC1-Bax-mediated mitochondrial apoptosis pathway. Cell Mol Biol Lett. 2024;29(1):47.

[47] ZhangX, HuangT, ZhaiH, et al. Inhibition of lysine-specific demethylase 1A suppresses neointimal hyperplasia by targeting bone morphogenetic protein 2 and mediating vascular smooth muscle cell phenotype. Cell Prolif. 2020;53(1):e12711.

[48] LiDY, BuschA, JinH, et al. H19 induces abdominal aortic aneurysm development and progression. Circulation. 2018;138(15):1551-1568.

[49] ZhaoG, ZhaoY, LuH, et al. BAF60c prevents abdominal aortic aneurysm formation through epigenetic control of vascular smooth muscle cell homeostasis. J Clin Invest. 2022;132(21):e158309.

RIGHTS & PERMISSIONS

2024 The Author(s). Cell Proliferation published by Beijing Institute for Stem Cell and Regenerative Medicine and John Wiley & Sons Ltd.